SAGE PRO

Home / Research / Concord Biotech Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Concord Biotech Limited — Q2 FY27 Results Analysis

Broad molecule growth increased sales

Published · Quarter Q2 FY27 · CONCORDBIO

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Quarterly revenue

Q2 FY26₹247.1 crore
Q2 FY27₹309.1 crore
CHART 2

Quarterly EBITDA

Q2 FY26₹88.5 crore
Q2 FY27₹104.4 crore
CHART 3

Quarterly PAT

Q2 FY26₹63.1 crore
Q2 FY27₹69.6 crore
CHART 4

Half-year revenue

H1 FY26₹451.1 crore
H1 FY27₹566.6 crore
ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Broad molecule growth increased sales

Quarterly revenue changed from 247.1 ₹ crore (Q2 FY26) to 309.1 ₹ crore (Q2 FY27). Broad molecule growth increased sales.

Watch: Track repeat orders

RESEARCH INSIGHT

Profit grew slower than sales

Quarterly EBITDA changed from 88.5 ₹ crore (Q2 FY26) to 104.4 ₹ crore (Q2 FY27). Profit grew slower than sales.

Watch: Inspect product mix

RESEARCH INSIGHT

PAT rose about 10%

Quarterly PAT changed from 63.1 ₹ crore (Q2 FY26) to 69.6 ₹ crore (Q2 FY27). PAT rose about 10%.

Watch: Check taxes

RESEARCH INSIGHT

H1 revenue rose 26%

Half-year revenue changed from 451.1 ₹ crore (H1 FY26) to 566.6 ₹ crore (H1 FY27). H1 revenue rose 26%.

Watch: Compare similar period

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Quarter ended 30 September 2026 · Stance WATCH · original issuer/exchange sources. Concord Biotech offers differentiated fermentation and specialty pharma product exposure, but its quarter illustrates that sales growth is not identical to earnings growth. Revenue rose roughly 25% to ₹309.1 crore, EBITDA about 18% to ₹104.4 crore and PAT about 10% to ₹69.6 crore. WATCH, contingent on regulatory delivery, repeat orders and sustainable margin, not unverified valuation or product-pipeline multiples. [S1][S2]

Decision metricEarlier referenceLatest reference
Quarterly revenue247.1 ₹ crore (Q2 FY26)309.1 ₹ crore (Q2 FY27)
Quarterly EBITDA88.5 ₹ crore (Q2 FY26)104.4 ₹ crore (Q2 FY27)
Quarterly PAT63.1 ₹ crore (Q2 FY26)69.6 ₹ crore (Q2 FY27)
Half-year revenue451.1 ₹ crore (H1 FY26)566.6 ₹ crore (H1 FY27)
Half-year EBITDA149.9 ₹ crore (H1 FY26)186.8 ₹ crore (H1 FY27)
Half-year PAT107.1 ₹ crore (H1 FY26)127.3 ₹ crore (H1 FY27)
Derived quarterly EBITDA margin35.8 % (Q2 FY26)33.8 % (Q2 FY27)
Q2 growth comparison25 % YoY (Revenue)18 % YoY (EBITDA)

Key takeaways: Quarterly revenue: Broad molecule growth increased sales. Quarterly EBITDA: Profit grew slower than sales. Quarterly PAT: PAT rose about 10%. Half-year revenue: H1 revenue rose 26%. Half-year EBITDA: H1 EBITDA rose 25%. Half-year PAT: H1 PAT grew 19%. All comparisons follow the issuer's specified dates, basis and units. The separate graphical Investment Briefing precedes the detailed main report.

Chapter 1 — Investment decision and valuation burden

Concord Biotech offers differentiated fermentation and specialty pharma product exposure, but its quarter illustrates that sales growth is not identical to earnings growth. Revenue rose roughly 25% to ₹309.1 crore, EBITDA about 18% to ₹104.4 crore and PAT about 10% to ₹69.6 crore. WATCH, contingent on regulatory delivery, repeat orders and sustainable margin, not unverified valuation or product-pipeline multiples. [S1][S2]

Issuer-specific financial checks and decisions

  • Quarterly revenue: 309.1 ₹ crore (Q2 FY27) against 247.1 ₹ crore (Q2 FY26). Broad molecule growth increased sales; Track repeat orders. [S2]
  • Quarterly EBITDA: 104.4 ₹ crore (Q2 FY27) against 88.5 ₹ crore (Q2 FY26). Profit grew slower than sales; Inspect product mix. [S2]
  • Quarterly PAT: 69.6 ₹ crore (Q2 FY27) against 63.1 ₹ crore (Q2 FY26). PAT rose about 10%; Check taxes. [S2]

Monitoring interpretation. Broad molecule growth increased sales. The practical next-quarter test is: track repeat orders. Profit grew slower than sales. The practical next-quarter test is: inspect product mix. PAT rose about 10%. The practical next-quarter test is: check taxes. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 2 — Quarter and H1 financials and earnings quality

The issuer presented consolidated Q2 revenue ₹309.1 crore versus ₹247.1 crore, EBITDA ₹104.4 crore versus ₹88.5 crore and PAT ₹69.6 crore versus ₹63.1 crore. H1 revenue ₹566.6 crore versus ₹451.1 crore, H1 EBITDA ₹186.8 crore versus ₹149.9 crore, and H1 PAT ₹127.3 crore versus ₹107.1 crore show six-month growth. Derived Q2 EBITDA margin around 33.8% compared with 35.8% is based on rounded figures, not a separately certified financial statement measure. [S1][S2]

Issuer-specific financial checks and decisions

  • Quarterly PAT: 69.6 ₹ crore (Q2 FY27) against 63.1 ₹ crore (Q2 FY26). PAT rose about 10%; Check taxes. [S2]
  • Half-year revenue: 566.6 ₹ crore (H1 FY27) against 451.1 ₹ crore (H1 FY26). H1 revenue rose 26%; Compare similar period. [S2]
  • Half-year EBITDA: 186.8 ₹ crore (H1 FY27) against 149.9 ₹ crore (H1 FY26). H1 EBITDA rose 25%; Test recurring margin. [S2]

Monitoring interpretation. PAT rose about 10%. The practical next-quarter test is: check taxes. H1 revenue rose 26%. The practical next-quarter test is: compare similar period. H1 EBITDA rose 25%. The practical next-quarter test is: test recurring margin. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 3 — Product, segment and channel economics

Immunosuppressants, anti-infectives, antifungals and oncology products drive a regulated molecule portfolio. Management described growth across categories and geographies, broader wallet share from current customers and advanced discussions with new clients. New customer qualification takes time and may require formulation, manufacturing and regulatory investment. Product breadth helps mitigate concentration but can also change operating margin; a pipeline is not booked sales. [S1][S2]

Issuer-specific financial checks and decisions

  • Half-year EBITDA: 186.8 ₹ crore (H1 FY27) against 149.9 ₹ crore (H1 FY26). H1 EBITDA rose 25%; Test recurring margin. [S2]
  • Half-year PAT: 127.3 ₹ crore (H1 FY27) against 107.1 ₹ crore (H1 FY26). H1 PAT grew 19%; Validate cash conversion. [S2]
  • Derived quarterly EBITDA margin: 33.8 % (Q2 FY27) against 35.8 % (Q2 FY26). Calculated margin reduced by ~2 points; Check audited ratio. [S2]

Monitoring interpretation. H1 EBITDA rose 25%. The practical next-quarter test is: test recurring margin. H1 PAT grew 19%. The practical next-quarter test is: validate cash conversion. Calculated margin reduced by ~2 points. The practical next-quarter test is: check audited ratio. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 4 — Execution promises, milestones and Q&A challenges

The presentation described a USFDA inspection of formulation Unit II at Valthera, Ahmedabad with one procedural observation characterized as unrelated to GMP. It referenced approvals of tofacitinib and mycophenolate mofetil oral suspension. The newly launched Inspira dermatology division is an extension of the commercial platform, not yet proof of durable earnings. Management's target to introduce two or three products a year is an aspiration requiring actual approval, manufacturing and launch evidence. [S1][S2]

Issuer-specific financial checks and decisions

  • Derived quarterly EBITDA margin: 33.8 % (Q2 FY27) against 35.8 % (Q2 FY26). Calculated margin reduced by ~2 points; Check audited ratio. [S2]
  • Q2 growth comparison: 18 % YoY (EBITDA) against 25 % YoY (Revenue). Sales growth outpaced EBITDA; Isolate mix. [S2]
  • Operating versus PAT growth: 10 % YoY (PAT) against 18 % YoY (EBITDA). Profit conversion was weaker; Review below-operating costs. [S2]

Monitoring interpretation. Calculated margin reduced by ~2 points. The practical next-quarter test is: check audited ratio. Sales growth outpaced EBITDA. The practical next-quarter test is: isolate mix. Profit conversion was weaker. The practical next-quarter test is: review below-operating costs. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 5 — Operating cash, capex, debt and payback

Regulated pharma commercialization relies on working capital, validation, production yields and stability of customer orders. A one-for-one bonus issue changes the share denominator but does not generate operating cash. The accepted Q2 results do not establish a complete audited project capex, debt or free-cash-flow bridge, so no leveraged-valuation input should be invented. Investors should look for the next cash-flow statement and launch economics to validate the stated investment narrative. [S1][S2]

Issuer-specific financial checks and decisions

  • Operating versus PAT growth: 10 % YoY (PAT) against 18 % YoY (EBITDA). Profit conversion was weaker; Review below-operating costs. [S2]
  • H1 growth balance: 25 % YoY (EBITDA) against 26 % YoY (Revenue). H1 profit almost matched sales; Review second half. [S2]
  • H1 net income growth: 19 % YoY (PAT) against 25 % YoY (EBITDA). Net earnings rose less than EBITDA; Review tax. [S2]

Monitoring interpretation. Profit conversion was weaker. The practical next-quarter test is: review below-operating costs. H1 profit almost matched sales. The practical next-quarter test is: review second half. Net earnings rose less than EBITDA. The practical next-quarter test is: review tax. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 6 — Bull, base and bear conditional scenarios

Bull: continued double-digit growth with sustained regulatory compliance, repeat exports and a recovery in product mix margin. Base: broad growth continues but new approvals and new-division investments hold profit growth below sales growth. Bear: quality issues, slow regulatory approvals, pricing pressure or poor unit utilization reduce cash conversion. These conditional cases are monitoring disciplines, not claimed probabilities or stock-price returns. [S1][S2]

Issuer-specific financial checks and decisions

  • Quarterly revenue: 309.1 ₹ crore (Q2 FY27) against 247.1 ₹ crore (Q2 FY26). Broad molecule growth increased sales; Track repeat orders. [S2]
  • Quarterly EBITDA: 104.4 ₹ crore (Q2 FY27) against 88.5 ₹ crore (Q2 FY26). Profit grew slower than sales; Inspect product mix. [S2]
  • Quarterly PAT: 69.6 ₹ crore (Q2 FY27) against 63.1 ₹ crore (Q2 FY26). PAT rose about 10%; Check taxes. [S2]

Monitoring interpretation. Broad molecule growth increased sales. The practical next-quarter test is: track repeat orders. Profit grew slower than sales. The practical next-quarter test is: inspect product mix. PAT rose about 10%. The practical next-quarter test is: check taxes. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Chapter 7 — Investor action plan and quarterly monitoring

WATCH quarterly revenue ₹309.1 crore, EBITDA ₹104.4 crore and PAT ₹69.6 crore with explicit Q2 FY26 comparators. Track Unit II compliance, actual product launches, net customer additions and repeat-orders, plus H1 revenue ₹566.6 crore against period-matched prior data. Strengthen conviction only when new business translates into recurring after-tax cash and a verified valuation permits margin-of-safety analysis. [S1][S2]

Issuer-specific financial checks and decisions

  • Quarterly PAT: 69.6 ₹ crore (Q2 FY27) against 63.1 ₹ crore (Q2 FY26). PAT rose about 10%; Check taxes. [S2]
  • Half-year revenue: 566.6 ₹ crore (H1 FY27) against 451.1 ₹ crore (H1 FY26). H1 revenue rose 26%; Compare similar period. [S2]
  • Half-year EBITDA: 186.8 ₹ crore (H1 FY27) against 149.9 ₹ crore (H1 FY26). H1 EBITDA rose 25%; Test recurring margin. [S2]

Monitoring interpretation. PAT rose about 10%. The practical next-quarter test is: check taxes. H1 revenue rose 26%. The practical next-quarter test is: compare similar period. H1 EBITDA rose 25%. The practical next-quarter test is: test recurring margin. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.

Supporting issuer and exchange filings

[S1] Concord Biotech Limited Q2 FY27 earnings-call transcript — management discussion and analyst questions for the September 2026 quarter. [S2] — issuer financial and operating data.

Interpretive limits: Future product launches, order contracts, customer discussions, raw-material effects and project milestones are cited as management commentary where relevant, not realized future profits. Valuation figures, project payback, market prices, leverage and cash conversions are omitted where the saved issuer evidence is inadequate.

Additional company evidence

CHART 5

Half-year EBITDA

H1 FY26₹149.9 crore
H1 FY27₹186.8 crore
CHART 6

Half-year PAT

H1 FY26₹107.1 crore
H1 FY27₹127.3 crore
CHART 7

Derived quarterly EBITDA margin

Q2 FY2635.8%
Q2 FY2733.8%
CHART 8

Q2 growth comparison

Revenue25 % YoY
EBITDA18 % YoY
SOURCE REFERENCES

Original disclosures and investor presentations

  1. Issuer disclosure

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.